虽然在精神分裂症的死后研究中已经报道了α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)型受体的表达改变,这些发现是不一致的。因此,我们旨在系统回顾调查精神分裂症中AMPA受体表达的验尸研究.
在2021年2月3日,使用Medline和Embase,对与健康个体相比,精神分裂症中AMPA受体亚基表达或受体结合的验尸研究进行了系统的文献检索。
从1360份初始报告中确定了39篇相关文章。背外侧前额叶皮质(DLPFC)是研究最多的区域(15项研究),其次是内侧颞叶(8项研究)。对于DLPFC,4/15研究(26.7%)显示,与对照组相比,精神分裂症患者的AMPA受体结合或亚基表达增加,特别是在GRIA1和GRIA4中,2/15的研究(13.3%)报告下降,特别是在GRIA2中,8/15研究(56.7%)发现无显著差异.与对照组相比,在精神分裂症患者海马亚区的6/8研究中观察到表达或受体结合降低(75.0%)。而其他两项研究没有发现显著差异。
已发表的数据报道了精神分裂症患者海马中亚基表达或受体结合减少。这些发现在其他大脑区域不一致,这可能是由于这个群体的异质性,各种学习设计,死后的生理变化,研究数量有限。未来的体内研究有必要检查人类大脑中的AMPA受体表达,以及他们的全面临床特征。
While altered expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (
AMPA) type receptor has been reported in postmortem studies of schizophrenia, these findings are inconsistent. Therefore, we aimed to systematically
review postmortem studies that investigated
AMPA receptor expressions in schizophrenia.
A systematic literature search was conducted for postmortem studies that measured
AMPA receptor subunit expressions or receptor bindings in schizophrenia compared to healthy individuals on February 3, 2021, using Medline and Embase.
A total of 39 relevant articles were identified from 1360 initial reports. The dorsolateral prefrontal cortex (DLPFC) was the most investigated region (15 studies), followed by the medial temporal lobe (8 studies). For the DLPFC, 4/15 studies (26.7%) showed increased
AMPA receptor binding or subunit expression in patients with schizophrenia compared to that in controls, especially in GRIA1 and GRIA4, 2/15 studies (13.3%) reported a decrease, particularly in GRIA2, and 8/15 studies (56.7%) found no significant differences. A decreased expression or receptor binding was observed in 6/8 studies (75.0%) in the subregions of the hippocampus in patients with schizophrenia compared to that in controls, whereas the other two studies found no significant differences.
Published data have reported decreased subunit expression or receptor binding in the hippocampus in schizophrenia. These findings were inconsistent in other brain regions, which might be due to the heterogeneity of this population, various study design, physiological changes after death, and limited number of studies. Future in vivo studies are warranted to examine
AMPA receptor expressions in human brains, together with their comprehensive clinical characterization.